# AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas

> **NCT02831257** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 18 (actual)

## Conditions studied

- Neurofibromatosis 2
- Meningioma

## Interventions

- **DRUG:** AZD2014

## Key facts

- **NCT ID:** NCT02831257
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-31
- **Primary completion:** 2019-05-31
- **Final completion:** 2020-10-01
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-06-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02831257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02831257, "AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02831257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*